PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Orion shifts R&D focus to cancer and pain drugs, axes 32 employees

Orion is the latest biotech to finalize an organizational restructuring that has resulted in employee cuts.

The Finnish biotech revealed back in March that it would be stepping away from its focus on neurodegenerative, rare diseases and chronic obstructive pulmonary disease treatments, looking to prioritize cancer and pain drugs moving forward. It has now been announced that the changes have been made.

The change in direction doesn’t come as a surprise, as Orion also announced earlier this month that it was partnering with Chinese company Jemincare to develop and bring to market a treatment for acute and chronic pain. The 32 employees that will be let go are positions that will become redundant because of this agreement.

Orion added that the refocus of its research and drug development won’t be affecting the current portfolio and products on the market. The biotech will keep manufacturing and selling its drugs, as well as continue investing in its pulmonary drugs.

Leading the shift is a drug developed in partnership with Bayer and approved by the FDA in 2019 — Nubeqa, a prostate cancer treatment. The company is also developing other prostate cancer drugs.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026